DE69842141D1 - Ein tumorsuppressor mit der bezeichnung ts10q23.3 - Google Patents

Ein tumorsuppressor mit der bezeichnung ts10q23.3

Info

Publication number
DE69842141D1
DE69842141D1 DE69842141T DE69842141T DE69842141D1 DE 69842141 D1 DE69842141 D1 DE 69842141D1 DE 69842141 T DE69842141 T DE 69842141T DE 69842141 T DE69842141 T DE 69842141T DE 69842141 D1 DE69842141 D1 DE 69842141D1
Authority
DE
Germany
Prior art keywords
tumorsuppressor
designated
tumorsuppressor designated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69842141T
Other languages
German (de)
English (en)
Inventor
Peter Steck
Mark A Pershouse
Samar A Jasser
W K Yung
Sean V Tavtigian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25152739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69842141(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of DE69842141D1 publication Critical patent/DE69842141D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69842141T 1997-01-30 1998-01-08 Ein tumorsuppressor mit der bezeichnung ts10q23.3 Expired - Lifetime DE69842141D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/791,115 US6262242B1 (en) 1997-01-30 1997-01-30 Tumor suppressor designated TS10Q23.3
PCT/US1998/000353 WO1998033907A1 (en) 1997-01-30 1998-01-08 A tumor suppressor designated ts10q23.3

Publications (1)

Publication Number Publication Date
DE69842141D1 true DE69842141D1 (de) 2011-04-07

Family

ID=25152739

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69842141T Expired - Lifetime DE69842141D1 (de) 1997-01-30 1998-01-08 Ein tumorsuppressor mit der bezeichnung ts10q23.3

Country Status (14)

Country Link
US (1) US6262242B1 (enExample)
EP (2) EP2366712A3 (enExample)
JP (5) JP2001511002A (enExample)
AR (1) AR011607A1 (enExample)
AT (1) ATE499444T1 (enExample)
AU (1) AU745296B2 (enExample)
CA (1) CA2278849C (enExample)
DE (1) DE69842141D1 (enExample)
DK (1) DK0972024T4 (enExample)
ES (1) ES2361044T5 (enExample)
IL (1) IL131168A0 (enExample)
PT (1) PT972024E (enExample)
WO (1) WO1998033907A1 (enExample)
ZA (1) ZA98756B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
WO1998034624A1 (en) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Use of the p-ten suppressor gene in diagnosis and treatment of cancer
US6225120B1 (en) 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
CA2301199C (en) * 1997-08-26 2013-02-05 Myriad Genetics, Inc. A tumor suppressor designated ts10q23.3
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
AU2002359697A1 (en) * 2001-12-20 2003-07-09 Tularik Inc. Identification of an amplified gene and target for drug intervention
WO2005044091A2 (en) * 2003-11-05 2005-05-19 Board Of Regents, The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Inst Inc método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
US9617601B2 (en) 2011-12-30 2017-04-11 Abbott Molecular Inc. Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
FR2616841A1 (fr) 1987-06-17 1988-12-23 Rauner Hans Perfectionnements au systeme de bloquage en position ouverte a levier de serrage pivotant, pour fiches et paumelles de portes et de fenetres
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
KR19990067011A (ko) 1995-10-23 1999-08-16 임페리얼 캔서 리서치 테크놀로지 리미티드 암에 대한 감수성 진단 및 그 치료방법
CA2301199C (en) * 1997-08-26 2013-02-05 Myriad Genetics, Inc. A tumor suppressor designated ts10q23.3
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
PT972024E (pt) 2011-05-05
CA2278849C (en) 2016-04-19
ZA98756B (en) 1998-08-25
JP4768783B2 (ja) 2011-09-07
US6262242B1 (en) 2001-07-17
WO1998033907A1 (en) 1998-08-06
JP2009039107A (ja) 2009-02-26
EP0972024A1 (en) 2000-01-19
JP2013128485A (ja) 2013-07-04
EP2366712A3 (en) 2012-11-14
IL131168A0 (en) 2001-01-28
CA2278849A1 (en) 1998-08-06
AU6018998A (en) 1998-08-25
JP2001511002A (ja) 2001-08-07
DK0972024T3 (da) 2011-04-26
AU745296B2 (en) 2002-03-21
EP2366712A2 (en) 2011-09-21
DK0972024T4 (da) 2014-07-07
ATE499444T1 (de) 2011-03-15
EP0972024B1 (en) 2011-02-23
JP5202583B2 (ja) 2013-06-05
JP2014155493A (ja) 2014-08-28
ES2361044T3 (es) 2011-06-13
AR011607A1 (es) 2000-08-30
JP2010259438A (ja) 2010-11-18
ES2361044T5 (es) 2014-10-01
EP0972024B2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
NO2006016I1 (no) 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
PT993456E (pt) 4,5-diaril-imidazoles 2-substituidos
FR2764014B1 (fr) Unite a arbre-et-moyeu
NO996106D0 (no) 4" - substituert - 9 -deokso-9A-AZA-9A-Homoerytromycin A- derivater
ES1029611Y (es) Un zapato.
DE69729362D1 (de) Ein Verbinder
DE69823658D1 (de) Ein laser
DK0966477T3 (da) 3'-N-oxid, 3'-N-dimethylamin, 9-oxim-erythromycin A-derivater
DE69842141D1 (de) Ein tumorsuppressor mit der bezeichnung ts10q23.3
DE69623091D1 (de) Ein Schalter
ZA984085B (en) A novel salt.
DE69720372D1 (de) Ein photoapparat
DE69510301D1 (de) Ein Flächenbelag
DE69811400D1 (de) Wachsapplikator
DE59809523D1 (de) Modulation mit mehrfacher Auflösung
NO985861L (no) Bjelkelagselement
ID24047A (id) Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on
ID20352A (id) Bahan herbisida 3,5-difluoropiridin
DK0914902T3 (da) Dyseindretning
DE69826234D1 (de) Ein hydroformierungsverfahren
DE69624460D1 (de) Ein Verstärker mit niedrigem Offset
FR2750612B1 (fr) Manege a pedalier
ITTE940003A0 (it) Tricocyn a.c.
DE69720422D1 (de) Ein Gerüstelement
ATE227081T1 (de) Ein 2-imidazol-5-on enthaltende, neue fungizide zusammensetzung